USP8 and cholangiocarcinoma: In solid tumors, including gastric, hepatocellular, cholangiocarcinoma, and pancreatic cancer, elevated USP8 expression suppresses anti-tumor immunity and drives tumor proliferation, invasion, and resistance to targeted therapies [35,41,42,43,44,45].